BioMed Research International / 2011 / Article / Tab 1

Review Article

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

Table 1

Therapeutic strategies in MDS depending of risk stratifying (adapted from [59, 60]).

Low-risk MDSHigh-risk MDS

Survival3–10 years<1.5 years
Risk of AML transformationLow rateHigh rate
WHO entitiesRA, RARS, RCUD, RCMD, MDS-U, MDS del(5q)RAEB (−1, −2)
IPSS Score (see [12])Low, Int-1 (score 0-1.0)Int-2, high (score ≥ 1.5)
Approved and applied drugs/therapiesGrowth factors: Erythropoietin, G-CSFDecitabine, 5-azacitidine
Immune therapy: steroids, cyclosporin, antithymocyte globulinInvestigational
Lenalidomide: 5q31Intensive chemotherapy
Decitabine, 5-azacitidine(Younger, karyotype diploid), allogeneic stem cell transplantation
Iron chelationIron chelation
Translocation (5;12) or 5q23Translocation (5;12) or 5q23
variant (PDGFR-B): Imatinibvariant (PDGFR-B): Imatinib
Future therapeutic perspectivesCombination with specific HDAC-Inhibitors

Abbrevations. AML: acute myeloid leukaemia; G-CSF: granulocyte-colony-stimulating factor; IPSS: International Prognostic Scoring System; MDS-U: MDS unclassifiable; MDS del(5q): MDS associated with isolated deletion of chromosome 5q; PDGFR-B: platelet-derived growth factor receptor B; RA: refractory anemia; RAEB: RA with excess blasts; RARS: RA with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCUD: refractory cytopenia with unilinease dysplasia.